We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Icosavax, Inc. (“Icosavax” or the “Company”) (NASDAQ: ICVX), in connection with its acquisition by a subsidiary of AstraZeneca via tender offer.  Under the merger agreement, the Company’s shareholders will receive $15.00 per share, plus a non-tradable contingent value right (“CVR”) for up to $5.00 per share.

Weiss Law is investigating whether (i) the Icosavax board acted in the best interests of Company shareholders in agreeing to the merger, (ii) the $15.00 merger consideration adequately compensates Icosavax shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.  Notably, the merger consideration is below the $26.50 median price target set by analysts, and at least one analyst set a price target for the Company of $30 per share, $15.00 above the merger price.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com